|
Age at baseline
|
|
18–29 years
|
333.96 (2.4%)
|
286.02 (2.5%)
|
47.94 (2.1%)
|
< 0.0001
|
|
30–39 years
|
3050.51 (21.8%)
|
2699.57 (23.1%)
|
350.94 (15.1%)
| |
|
40–59 years
|
9754.3 (69.7%)
|
7973.02 (68.3%)
|
1781.28 (76.8%)
|
|
>=60 years
|
846.91 (6.1%)
|
708.10 (6.1%)
|
138.81 (6.0%)
|
|
Gender and transmission group
|
|
Men who have sex with men
|
5462.59 (39.1%)
|
4392.05 (37.6%)
|
1070.41 (46.2%)
|
< 0.0001
|
|
Injecting drug users
|
2393.23 (17.1%)
|
2087.84 (17.9%)
|
305.39 (13.2%)
| |
|
Other men
|
2788.01 (19.9%)
|
2258.16 (19.4%)
|
529.94 (22.8%)
|
|
Other women
|
3341.84 (23.9%)
|
2928.67 (25.1%)
|
413.17 (17.8%)
|
|
Geographic origin
|
|
Sub-Saharan Africa
|
1218.56 (8.7%)
|
970.62 (8.3%)
|
247.94 (10.7%)
|
0.0002
|
|
Other
|
12,767.12 (91.3%)
|
10,696.10 (91.7%)
|
2071.02 (89.3%)
| |
|
HCV co-infection status
|
|
No
|
11,650.70 (83.3%)
|
9643.24 (82.7%)
|
2007.47 (86.6%)
|
< 0.0001
|
|
Yes
|
2334.96 (16.7%)
|
2023.47 (17.3%)
|
311.49 (13.4%)
| |
|
Centre - Total follow-up of heavily treated individuals
|
|
< 140 P-Y
|
2575.17 (18.4%)
|
2118.09 (18.2%)
|
457.02 (19.7%)
|
< 0.0001
|
|
140–240 P-Y
|
3254.79 (23.3%)
|
2717.26 (23.3%)
|
537.53 (23.2%)
| |
|
240–400 P-Y
|
3895.42 (27.9%)
|
3354.69 (28.8%)
|
540.73 (23.3%)
|
|
≥ 400 P-Y
|
4260.31 (30.5%)
|
3476.68 (29.8%)
|
783.63 (33.8%)
|
|
Calendar period
|
|
2005–2006
|
8760.93 (62.6%)
|
8517.74 (73.0%)
|
243.19 (10.5%)
|
< 0.0001
|
|
2007–2008
|
3779.28 (27.0%)
|
2280.19 (19.5%)
|
1499.09 (64.6%)
| |
|
2009–2011
|
1445.46 (10.3%)
|
868.78 (7.4%)
|
576.68 (24.9%)
|
|
Nadir CD4 count (cells/mm3) at baseline
|
|
< 50
|
5090.31 (36.4%)
|
3973.69 (34.1%)
|
1116.62 (48.2%)
|
< 0.0001
|
|
50–100
|
2395.85 (17.1%)
|
1989.13 (17.0%)
|
406.72 (17.5%)
| |
|
100–200
|
3564.30 (25.5%)
|
3075.84 (26.4%)
|
488.46 (21.1%)
|
|
≥ 200
|
2935.22 (21.0%)
|
2628.05 (22.5%)
|
307.16 (13.2%)
|
|
CD4 count (cells/mm3) at baseline
|
|
< 200
|
4879.74 (34.9%)
|
3871.50 (33.2%)
|
1008.24 (43.5%)
|
< 0.0001
|
|
200–350
|
4083.24 (29.2%)
|
3521.03 (30.2%)
|
562.21 (24.2%)
| |
|
350–500
|
2537.01 (18.1%)
|
2173.42 (18.6%)
|
363.59 (15.7%)
|
|
≥ 500
|
2485.68 (17.8%)
|
2100.76(18.0%)
|
384.92 (16.6%)
|
|
VL (copies/mL) at baseline
|
|
50–500
|
2824.38 (20.2%)
|
2301.04 (19.7%)
|
523.34 (22.6%)
|
< 0.0001
|
|
500–5000
|
3255.58 (23.3%)
|
2763.23 (23.7%)
|
492.35 (21.2%)
| |
|
5000–30,000
|
2930.25 (21.0%)
|
2408.75 (20.6%)
|
521.50 (22.5%)
|
|
30,000–100,000
|
2501.51 (17.9%)
|
2059.86 (17.7%)
|
441.65 (19.0%)
|
|
> 100,000
|
2473.97 (17.7%)
|
2133.85 (18.3%)
|
340.12 (14.7%)
|
|
Previous AIDS defining events at baseline
|
|
No
|
8274.24 (59.2%)
|
7116.34 (61.0%)
|
1157.90 (49.9%)
|
< 0.0001
|
|
Yes
|
5711.44 (40.8%)
|
4550.31 (39.0%)
|
1161.06 (50.1%)
| |
|
Prophylaxis (Cotrimoxazole, Dapsone, Pentamidine)
|
|
Not eligible (CD4 > 200)
|
8093.10 (57.9%)
|
6969.47 (59.7%)
|
1123.63 (48.5%)
|
< 0.0001
|
|
No
|
1821.36 (13.0%)
|
1378.35 (11.8%)
|
443.01 (19.1%)
| |
|
Yes
|
4071.22 (29.1%)
|
3318.89 (28.5%)
|
752.33 (32.4%)
|
|
Number of prior ARVs
|
|
5–8
|
3749.64 (26.8%)
|
3609.96 (30.9%)
|
139.69 (6.0%)
|
< 0.0001
|
|
9–10
|
3816.28 (27.3%)
|
3520.84 (30.2%)
|
295.44 (12.7%)
| |
|
11–13
|
4084.10 (29.2%)
|
3281.11 (28.1%)
|
802.99 (34.6%)
|
|
> 13
|
2335.66 (16.7%)
|
1254.81 (10.8%)
|
1080.85 (46.6%)
|
